Cellcentric Ltd.
Clinical trials sponsored by Cellcentric Ltd., explained in plain language.
-
New hope for patients with aggressive blood cancer that has stopped responding to treatment
Disease control Recruiting nowThis study is testing whether adding a new drug called inobrodib to two standard medications can help control multiple myeloma that has come back and no longer responds to available therapies. It will involve about 100 adults whose cancer has progressed despite trying several oth…
Phase: PHASE2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called CCS1477 (inobrodib) in patients with advanced blood cancers that have returned or stopped responding to standard treatments. The main goals are to check if the drug is safe, what side effects it causes, and if it shows signs of …
Phase: PHASE1, PHASE2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC